REG - ValiRx PLC - Commercial Update

ValiRxAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250430:nRSd7152Ga&default-theme=true

RNS Number : 7152G  ValiRx PLC  30 April 2025

 

ValiRx PLC

("ValiRx" or the "Company")

 

Commercial Update

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, is pleased to provide the
following update on the commercial activity of its wholly owned subsidiary
Inaphaea BioLabs ("Inaphaea").

Inaphaea is a pleased to announce the execution of an evaluation and
commercial use agreement ("Evaluation and Commercial Agreement") with UK based
Dominion Biotech Ltd ("Dominion") to co-market services based on a client
ownership model, where each company operates independently whilst marketing
and delivering services using their combined PDC biobanks. The Evaluation and
Commercial Agreement provides mutual access to Inaphaea's range of 66 cancer
types alongside Dominion's collected tumour samples with comprehensive genetic
profiling (NGS based mutation profiling and RNA-Seq expression analysis).
Access to PDCs and services by each company will be agreed on a case-by-case
basis subject to a minimum fee. The Evaluation and Commercial Agreement is for
a period of 12 months initially and may be extended in writing by mutual
agreement.

An evaluation use agreement ("Evaluation Agreement") has also been executed
with UK based Cellomatics Biosciences Ltd ("Cellomatics"). The Evaluation
Agreement initially focusses on in house evaluation of Inaphaea's Colorectal
Cancer PDCs by Cellomatics which, if successful, will be offered for
commercial services by Cellomatics and Inaphaea on terms to be agreed. Both
companies have also agreed to co-market their respective services. The
Evaluation Agreement is for a period of 12 months initially and may be
extended in writing by mutual agreement.

 

Mark Eccleston, CEO of ValiRx commented "We're pleased to announce two further
deals for Inaphaea's PDC biobank. Both deals demonstrate the commercial
potential and interest in the biobank and support our approach to cross
marketing to achieve better market awareness and penetration of this resource.
The Dominion deal brings a new angle whereby we can access additional,
prospectively collected models for clients whilst dominion benefits from our
established biobank. Cellomatics are a Nottingham based Contract Research
Organisation with an established client base and complementary pre-clinical
testing capabilities."

 

Anthony Holmes, CEO of Dominion commented "We're excited to partner with
Inaphaea to expand access to patient-derived cancer models for drug discovery
and development. This collaboration combines Dominion's expertise in
collecting and characterizing fresh tumour samples with Inaphaea's established
biobank of diverse cancer types, creating a powerful resource for
pharmaceutical companies seeking to improve clinical trial success rates. By
joining forces under this innovative client ownership model, we can offer
clients an even more comprehensive service while maintaining our independent
operations. We look forward to working with the Inaphaea team to accelerate
the development of more effective cancer therapies."

 

Shailendra Singh, CEO of Cellomatics commented "We are excited to announce the
execution of an Evaluation Agreement with Inaphaea BioLabs. This collaboration
marks an important step forward in expanding our oncology service offerings,
starting with the in-house evaluation of Inaphaea's Colorectal Cancer PDCs. If
successful, we look forward to jointly offering these cutting-edge models as
part of our commercial service portfolio. This partnership reflects
Cellomatics' commitment to innovation, collaboration, and delivering
meaningful value to our clients in the oncology space."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/lyapKP

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0025

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFZGZDLLGGKZM